Dr. Steven Sangha is a respected, board-certified gastroenterologist who has cared for patients in metro Atlanta for many years. He has extensive experience in general gastroenterology, routine colonoscopies, and particularly in managing inflammatory bowel disease (IBD). His patients know him to be a truly a genuine, caring, and personable physician.

Dr. Sangha earned his undergraduate and medical degrees from Emory University School of Medicine. He completed his internship and residency at the University of Texas Southwestern Medical Center and his gastroenterology fellowship at the University of Cincinnati College of Medicine. Dr. Sangha served as assistant professor at the University of Cincinnati, where he ran the university IBD clinic and was part of the IBD clinical trial team.

After completing his post-doctoral training, Dr. Sangha chose to make Georgia his home and returned to the Atlanta area to practice. He is affiliated with Emory St. Joseph's Hospital. When not in the office, Dr. Sangha enjoys scuba diving, hiking, swimming, gardening, running, and vinyl collecting.

Education

• Fellowship: Chief Fellow, Gastroenterology and Hepatology, University of Cincinnati College of Medicine
• Internship and Residency: Internal Medicine, University of Texas Southwestern Medical Center
• Doctor of Medicine: Emory University School of Medicine
• Bachelor of Arts: Chemistry & Asian Studies, Emory University

Certifications

• Gastroenterology: American Board of Internal Medicine (ABIM)
• Internal Medicine: American Board of Internal Medicine (ABIM)

Professional Memberships

• Member: American Gastroenterological Association (AGA), 2016 - present
• Member: American College of Gastroenterology (ACG), 2017 - present
• Member: American Association for the Study of Liver Disease (AASLD), 2018 - 2020

Awards, Honors, Distinctions

• Chief Fellow: Selected by the University of Cincinnati College of Medicine administration to represent and manage GI fellowship.
• 100 Honorary Senior, Emory University: One of 100 graduating seniors honored for outstanding contribution to the Emory community.

Clinical Research

June 2021 - April 2022
Sub-Investigator, "An Open-Label Extension of Study SERES-012 and Open-Label Program for Evaluating SER-109 in Adult Subjects with Recurrent Clostridioides Difficile Infection (RCDI)."

June 2021 - April 2022
Sub-Investigator, "A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately Active Ulcerative Colitis."

March 2021 - March 2022
Sub-Investigator, "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis."

Jan 2021 - April 2022
Sub-Investigator, "A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease Who Have Failed Anti-TNF therapy."

December 2020 - April 2022
Sub-Investigator, "Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode."

December 2020 - April 2022
Sub-Investigator, "A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis."

December 2020 - March 2021
Sub-Investigator, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis."

November 2020 - April 2022
Sub-Investigator, "Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease."

November 2020 - April 2022
Sub-Investigator, "A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease."

November 2020 - April 2022
Sub-Investigator, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional Therapies but Have Not Failed Biologic Therapy."

November 2020 - April 2022
Sub-Investigator, "A Phase 3, Randomized, Double-blind, Placebo-Controlled, 52-week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis."

October 2020 - April 2022
Sub-Investigator, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease Who Completed the Studies M14-431 or M14-433."

October 2020 - April 2022
Sub-Investigator, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy."

2020 - April 2022
Sub-Investigator, "A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohn's Disease."

October 2020 - April 2022
Sub-Investigator, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis."